News & Views

  • Shuwen Biotech and DiagnoCure Sign Exclusive License and Collaboration Agreement for Commercialising Previstage™ GCC Colorectal Cancer Staging Test in China

Shuwen Biotech and DiagnoCure Sign Exclusive License and Collaboration Agreement for Commercialising Previstage™ GCC Colorectal Cancer Staging Test in China

Jul 17 2014 Read 1621 Times

Shuwen Biotech Co. Ltd, a diagnostic company focused on licensing, developing and commercialising diagnostic kits and services for unmet clinical needs in China, has announced today that it has formed an alliance with the Canada-based DiagnoCure, Inc to commercialise the Previstage™ GCC colorectal cancer staging test in China. 

 

Under the exclusive license and collaboration agreement, DiagnoCure has granted Shuwen Biotech an exclusive license to commercialise the Previstage™ GCC colorectal cancer staging test in the Greater China Region (China, Hong Kong, and Taiwan).  Shuwen Biotech will conduct clinical trials in China on an IVD kit format of the Previstage™ test, and obtain a regulatory approval from the Chinese FDA for the kit.  Shuwen Biotech will manufacture the IVD kit in its own manufacturing facilities and market the kit to major Chinese hospitals.  In addition, Shuwen Biotech will also offer the Previstage™ testing service from its own clinical reference lab. 

 

“Shuwen Biotech is a leading molecular diagnostic company in China led by its Chairman and CEO Jay Z. Zhang, a diagnostic industry veteran, who was formerly a senior vice president at Myriad Genetics.  Collaborating with Jay and his team will undoubtedly create value for both corporations and most importantly help colon cancer patients receive the most appropriate treatment,” commented Dr Yves Fradet, President and Chief Medical Officer of DiagnoCure. 

 

“The ability to collaborate with DiagnoCure and to market Previstage™ GCC in the Greater China Region provides Shuwen with an exciting opportunity.   We strongly believe in the benefits of Previstage™ GCC to help in staging and better control of colorectal cancer, a condition afflicting unfortunately a growing number of patients in China,” said Mr Jay Z. Zhang.

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

International Labmate November 2019

November 2019

In This Edition Articles - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - The Separation and Purification of Glutamine Deri...

View all digital editions

Events

MEDICA 2019

Nov 18 2019 Dusseldorf, Germany

Cleanzone

Nov 19 2019 Frankfurt am Main, Germany

INCHEM TOKYO 2019

Nov 20 2019 Tokyo, Japan

Miconex

Nov 25 2019 Beijing, China

IFAT India

Dec 05 2019 New Delhi, India

View all events